IP Library Granted Patent US 8,182,890
Granted Patent B2
US 8,182,890 · App. 12/016,085 · Granted May 22, 2012

Biodegradable endoprostheses and methods for their fabrication

Assignee: Elixir Medical Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,182,890
App. No.
12/016,085
Granted
May 22, 2012
Kind
B2
Abstract

Biodegradable endoprostheses are formed from amorphous polymers having desirable biodegradation characteristics. The strength of such amorphous polymers is enhanced by annealing to increase crystallinity without substantially increasing the biodegradation time.

Claims (57)

1. A biodegradable stent prosthesis comprising,

a tubular body comprising a biodegradable polymeric material, wherein said tubular body has been formed using extrusion, molding, dipping, or spraying and has been treated, said biodegradable polymeric material is substantially amorphous after said treatment and has a T g greater than 37° C., and the stent prosthesis at 37° C. is radially expandable and has sufficient strength to support a blood vessel.

2. A biodegradable stent prosthesis comprising:

a tubular body comprising a biodegradable polymeric material, wherein said tubular body has been formed using extrusion, molding, dipping, or spraying and has been treated, said biodegradable polymeric material has a crystallinity of 10% to 30% after said treatment and has a Tg greater than 37° C., and the stent prosthesis at 37° C. is radially expandable and has sufficient strength to support a blood vessel.

3. A biodegradable stent prosthesis as in claim 1 or 2 , wherein the biodegradable polymeric material comprises a biodegradable polymer selected from the group consisting of poly-DL-Lactide, polylactide-co-glycolide, polylactide-co-polycaprolactone, poly (L-lactide-co-trimethylene carbonate), polytrimethylene carbonate and copolymers thereof; polyhydroxybutyrate and copolymers thereof; polyhydroxyvalerate and copolymers thereof; poly orthoesters and copolymers thereof; poly anhydrides and copolymers thereof; polylactide and copolymers thereof; polyglycolides and copolymers thereof; polycaprolactone and copolymers thereof; and polyiminocarbonates and copolymers thereof.

4. A biodegradable prosthesis as in claim 3 , wherein the polymer comprises a copolymer of L-lactide and glycolide.

5. A biodegradable prosthesis as in claim 4 , wherein the copolymer comprises 85% L-lactide and 15% glycolide by weight.

6. A biodegradable stent prosthesis as in claim 3 , wherein the biodegradable polymer is polylactide-co-glycolide or polylactide-co-polycaprolactone.

7. A biodegradable stent prosthesis as in claim 3 , wherein the biodegradable polymer is a copolymer comprising poly-L-lactide.

8. A biodegradable stent prosthesis as in claim 3 , wherein the biodegradable polymer is a homopolymer, copolymer, graft polymer, block polymer, or a blend of two or more homopolymers or copolymers.

9. A biodegradable stent prosthesis as in claim 3 , wherein the biodegradable polymer is a copolymer of polycaprolactone.

10. A biodegradable stent prosthesis as in claim 3 , wherein the biodegradable polymer is a polylactide-co-polycaprolactone polymer, a blend of a polylactide polymer and a polycaprolactone polymer, a polylactide-co-glycolide polymer, or a blend of a polylactide polymer and a glycolide polymer.

11. A biodegradable stent prosthesis as in claim 1 or 2 , wherein the treatment comprises at least one cycle of heating and cooling.

12. A biodegradable stent prosthesis as in claim 11 , wherein the treatment comprises at least two cycles of heating and cooling.

13. A biodegradable stent prosthesis as in claim 1 or 2 , wherein the treatment comprises exposure to radiation.

14. A biodegradable stent prosthesis as in claim 13 , wherein the radiation is gamma or e-beam radiation.

15. A biodegradable stent prosthesis as in claim 1 or 2 , wherein the biodegradable polymeric material comprises less than 3% monomer content.

16. A biodegradable stent prosthesis as in claim 1 or 2 , wherein the treatment comprises at least one of heating, cooling, pressurizing, addition of an additive, drawing in radial and/or longitudinal direction, cross linking, and exposure to radiation.

17. A biodegradable stent prosthesis as in claim 16 , wherein the additive is selected from the group consisting of nanoclay, nanotubes, nanoparticles, exfoliates, fibers, whiskers, platelets, nanopowders, fullerenes, nanospheres, and zeolites.

18. A biodegradable stent prosthesis as in claim 1 or 2 , wherein the prosthesis degrades substantially within 2 years.

19. A biodegradable stent prosthesis as in claim 1 or 2 , wherein the biodegradable polymeric material after the treatment has one or more properties selected from the group consisting of a yield strength of at least 50% of ultimate strength in water at 37° C., an elastic modulus of least 0.5 GPa in water at 37° C., a yield strain of at most 10% in water at 37° C., and a plastic strain of at least 20% in water at 37° C.

20. A biodegradable stent prosthesis as in claim 1 or 2 , wherein the biodegradable polymeric material after the treatment has a yield strain of at most 10% in water at 37° C. and a plastic strain of at least 20% in water at 37° C.

21. A biodegradable stent prosthesis as in claim 1 or 2 , wherein the stent prosthesis has a radial strength of at least 8 psi.

22. A biodegradable stent prosthesis as in claim 1 or 2 , wherein the stent prosthesis after the treatment has increased strength and period of biodegradation for the prosthesis is not substantially lengthened.

23. A biodegradable stent prosthesis as in claim 1 or 2 , wherein the biodegradable polymeric material after the treatment has a molecular weight from 100 KDa to 1000 KDa.

24. A biodegradable stent prosthesis as in claim 1 or 2 , wherein the stent prosthesis further comprises a drug.

25. A biodegradable stent prosthesis as in claim 24 , wherein the drug inhibits restenosis of a blood vessel.

26. A biodegradable stent prosthesis as in claim 24 , wherein the drug is rapamycin, everolimus, ABT 578, AP20840, AP23841, AP23573, CCI-779, deuterated rapamycin, TAFA93, tacrolimus, cyclosporine, TKB662, myriocin, paclitaxel, their analogues, pro-drug, metabolites, salts, or combination thereof.

27. A biodegradable stent prosthesis as in claim 1 or 2 , wherein the stent prosthesis further comprises an additional biodegradable polymer.

28. A biodegradable stent prosthesis as in claim 1 or 2 , wherein the tubular body further comprises a drug.

29. A biodegradable stent prosthesis of claim 1 or 2 wherein the tubular body has a diameter of about 1-1.5 times an intended deployment diameter of the stent prosthesis.

30. A biodegradable stent prosthesis as in claim 1 or 2 , wherein the treatment increases crystallinity of the biodegradable polymeric material by at least 20% of the original crystallinity.

31. A biodegradable stent prosthesis as in claim 1 or 2 , wherein the stent prosthesis has a radial strength of at least 3 psi.

32. A biodegradable stent prosthesis as in claim 1 or 2 , wherein the stent prosthesis retains at least 25% of strength after at least 1 month in physiological conditions.

33. A biodegradable stent prosthesis as in claim 1 or 2 , wherein the stent prosthesis retains at least 40% of strength after at least 1 month in physiological conditions.

34. A biodegradable stent prosthesis as in claim 1 or 2 , wherein the stent prosthesis retains at least 70% of strength after at least 1 month in physiological conditions.

35. A biodegradable stent prosthesis as in claim 1 or 2 , wherein the tubular body is patterned into the stent prosthesis.

36. A biodegradable stent prosthesis as in claim 35 , wherein the tubular body is patterned at an expanded diameter.

37. A biodegradable stent prosthesis as in claim 36 ,

wherein the diameter is larger than a crimped diameter.

38. A biodegradable stent prosthesis as in claim 35 , wherein the tubular body is patterned at an expanded diameter about 1 to 1.3 times larger than an intended deployed diameter of the stent prosthesis.

39. A biodegradable stent prosthesis as in claim 35 , wherein the tubular body is patterned before or after the treatment.

40. A biodegradable stent prosthesis as in claim 35 , wherein the tubular body undergoes the treatment before or after patterning.

41. A biodegradable stent prosthesis as in claim 35 , wherein the patterned tubular body is balloon expandable.

42. A biodegradable stent prosthesis as in claim 35 having a diameter of about 1 to 1.5 times of an intended deployment diameter of the stent prosthesis.

43. A biodegradable stent prosthesis as in claim 35 , wherein the stent prosthesis has a diameter that is substantially the same as the initial diameter of the tubular body.

44. A biodegradable stent prosthesis as in claim 35 , wherein the stent prosthesis is crimped to a diameter smaller than an intended deployment diameter of the stent prosthesis.

45. A biodegradable stent prosthesis as in claim 44 , wherein the stent prosthesis has a diameter of about 1 to 1.5 times the intended deployment diameter of the stent prosthesis.

46. A biodegradable stent prosthesis as in claim 1 or 2 , wherein said stent prosthesis has a recoil from an expanded condition of less than 10%.

47. A biodegradable stent prosthesis as in claim 1 or 2 , wherein said stent prosthesis has a yield strain of at most 10% and a plastic strain of at least 20%.

48. A biodegradable stent prosthesis as in claim 1 or 2 , wherein said tubular body has been treated in a substantially amorphous state.

49. A biodegradable stent prosthesis as in claim 1 or 2 wherein the tubular body has an initial diameter.

50. A biodegradable stent prosthesis as in claim 49 wherein the initial diameter of the tubular body is about 1 to 1.5 times of an intended deployment diameter of the stent prosthesis.

51. A biodegradable stent prosthesis as in claim 49 , wherein the tubular body after treatment has a diameter that is substantially the same as the initial diameter of the tubular body.

52. A biodegradable stent prosthesis as in claim 1 or 2 , wherein the stent prosthesis has one or more properties selected from the group consisting of a yield strength of at least 50% of ultimate strength in water at 37° C., an elastic modulus of least 0.5 GPa in water at 37° C., a yield strain of at most 10% in water at 37° C., and a plastic strain of at least 20% in water at 37° C.

53. A biodegradable stent prosthesis as in claim 1 or 2 , wherein the treatment comprises one or more treatments.

54. A biodegradable stent prosthesis as in claim 1 or 2 , wherein the stent prosthesis is expandable at body temperature from a crimped configuration.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2014
From: ELIXIR MEDICAL CORPORATION, A DELAWARE CORPORATION
To: ELIXIR MEDICAL CORPORATION, A CALIFORNIA CORPORATION
Reel/Frame 032907/0038 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2008
From: ZHENG, XIAOXIA; YAN, JOHN; BHAT, VINAYAK
To: ELIXIR MEDICAL CORPORATION
Reel/Frame 020636/0608 →
Continuity (2)
Provisional Application 60885700 · Jan 19, 2007
Related Publication 20080177374A1 · Jul 24, 2008